Phase 2 Study of Ruxolitinib in Chronic Myelomonocytic Leukemia Shows Potential for Improved Outcomes
A Phase 2 expansion study is underway to evaluate the efficacy of ruxolitinib in patients with CMML.
Indication
Clinical and regulatory intelligence for Chronic Myelomonocytic Leukemia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.